Compare Gilead Sciences, Inc. (GILD) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs New York Times Co — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while New York Times Co trades at $75.24 (market cap $12.18B). The key difference: Gilead Sciences, Inc. is far larger — about 13.4× New York Times Co's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NYT | |
|---|---|---|
Market Cap | $163.51B | $12.18B |
Sector | Health | Media |
52-Week High | $155.80 | $85.86 |
52-Week Low | $108.22 | $51.43 |
Enterprise Value | $178.05B | $11.57B |
Dividend Yield | 2.49% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
The New York Times (NYT) trades at $75.85, up 3.93% today, showing strong momentum with consistent earnings beats in recent quarters. Technicals are bullish with support at $75 and resistance at $76. Revenue grew to $2.82B in 2025, with net income margin expanding to 12.17%. The company maintains robust cash flow from operations at $584M and announced a $0.23 dividend payable July 23, 2026.
Outlook remains positive with Q2 2026 earnings expected at $0.67 EPS on August 5. Analysts project a $78 consensus target, though legal pressures from government subpoenas and OpenAI copyright disputes pose near-term risks. Valuation multiples like P/E of 32.28 suggest premium pricing relative to historical norms, requiring sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
